Blog

Jun 18, 2024, 6:41 PM
AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced it has named Dr. Wen-Hsuan Chang as Associate Vice President of Discovery and Early Development
Jun 18, 2024, 6:32 PM
AcuraStem proudly sponsored the recent IgNight ALS event in Washington, D.C., a poignant evening dedicated to celebrating Steve Gleason and his profound contributions to the ALS community
Jun 3, 2024, 4:19 PM
AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced the expansion of its team with three new team members, bringing a fresh influx of expertise to its pioneering platform.
May 17, 2024, 6:24 PM
AcuraStem’s Associate Vice President, Dr. Wen-Hsuan (Wen) Chang, to Present at 3rd Annual ALS Drug Development Summit and Participate in Panel and Roundtable Discussions
Feb 27, 2024, 8:12 PM
AcuraStem CEO, Sam Alworth, will present on the company's trailblazing approach to amyotrophic lateral sclerosis (ALS) therapies at the MDA Clinical & Scientific Conference on March 4th.
Feb 27, 2024, 5:39 PM
AcuraStem’s Head of Target Validation, Dr. Wen-Hsuan Chang, presented an update on the company's innovative UNC13A program at the 14th Annual California ALS Research Summit on January 19, 2024
Jan 30, 2024, 1:00 AM
AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial
Sep 25, 2023, 9:30 AM
Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase
Jun 15, 2023, 7:11 PM
AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, is pleased to announce its sponsorship of the Gordon Research Seminar and Conference on "Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases Mechanisms, Modeling and Translational Therapeutics."
May 29, 2023, 1:51 PM
Join AcuraStem's CEO, Sam Alworth, at the forthcoming 2023 BIO International Convention in Boston from June 5-8, 2023. AcuraStem is at the cutting edge of developing treatments for neurodegenerative diseases, including sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).